- Home
- NDLS vs BLUE Comparison
NDLS vs BLUE Comparison
Compare NDLS & BLUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NDLS
- BLUE
- Stock Information
- Founded
- NDLS 1995
- BLUE 1992
- Country
- NDLS United States
- BLUE United States
- Employees
- NDLS N/A
- BLUE N/A
- Industry
- NDLS Restaurants
- BLUE Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NDLS Consumer Discretionary
- BLUE Health Care
- Exchange
- NDLS Nasdaq
- BLUE Nasdaq
- Market Cap
- NDLS 45.2M
- BLUE 36.9M
- IPO Year
- NDLS 2013
- BLUE 2013
- Fundamental
- Price
- NDLS $0.74
- BLUE $4.99
- Analyst Decision
- NDLS Strong Buy
- BLUE Hold
- Analyst Count
- NDLS 2
- BLUE 7
- Target Price
- NDLS $3.00
- BLUE $44.60
- AVG Volume (30 Days)
- NDLS 133.2K
- BLUE 880.0K
- Earning Date
- NDLS 05-07-2025
- BLUE 05-14-2025
- Dividend Yield
- NDLS N/A
- BLUE N/A
- EPS Growth
- NDLS N/A
- BLUE N/A
- EPS
- NDLS N/A
- BLUE N/A
- Revenue
- NDLS $495,670,000.00
- BLUE $103,946,000.00
- Revenue This Year
- NDLS $5.37
- BLUE $205.45
- Revenue Next Year
- NDLS $0.68
- BLUE $3.74
- P/E Ratio
- NDLS N/A
- BLUE N/A
- Revenue Growth
- NDLS N/A
- BLUE 127.51
- 52 Week Low
- NDLS $0.55
- BLUE $3.20
- 52 Week High
- NDLS $2.20
- BLUE $28.60
- Technical
- Relative Strength Index (RSI)
- NDLS 31.20
- BLUE 63.72
- Support Level
- NDLS $0.79
- BLUE $3.20
- Resistance Level
- NDLS $0.95
- BLUE $4.45
- Average True Range (ATR)
- NDLS 0.09
- BLUE 0.10
- MACD
- NDLS -0.01
- BLUE 0.13
- Stochastic Oscillator
- NDLS 6.22
- BLUE 100.00
About NDLS Noodles & Company
Noodles & Co is a restaurant concept offering lunch and dinner within the fast-casual segment of the restaurant industry. The company's menu includes a variety of cooked-to-order dishes, including noodles and pasta, soups, salads and appetizers. The company also provides dining, pick-up and delivery services.
About BLUE bluebird bio Inc.
bluebird bio Inc is a biotechnology company engaged in researching, developing, and commercializing potentially curative gene therapies for severe genetic diseases based on its proprietary lentiviral vector (LVV) gene addition platform. The Company operates in a single segment, focusing on researching, developing and commercializing potentially transformative gene therapies for severe genetic diseases.